权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Slippery Omniphobic Coating for Hemodialysis Catheter to Resist Fibrin Sheathing and Infection and Improve Patient Outcomes

用于血液透析导管的光滑全疏涂层可抵抗纤维蛋白鞘和感染并改善患者预后

基本信息

批准号：
10759575
负责人：
Todd McFarland
金额：
$ 80.19万
依托单位：
FREEFLOW MEDICAL DEVICES, LLC
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10759575
关键词：
Acute Adhesions Adult Animals Back Bacteria Biological Blood Blood Circulation Blood Vessels Blood flow Candida Catheter-related bloodstream infection Catheters Cells Certification Clinical Complement Membrane Attack Complex Complication Cyclic GMP Cytolysis Device Safety Devices Dialysis procedure Domestic Sheep Effectiveness Engineering Euthanasia FDA approved Fibrin Fibrinogen Fluorocarbons Functional disorder Goals Good Manufacturing Process Hemodialysis Hemolysis Induction Histologic Hour Implant Incidence Indwelling Catheter Infection Liquid substance Manufacturer Marketing Medical Device Microbial Biofilms Pathway interactions Patient Care Patient-Focused Outcomes Patients Phase Polyurethanes Procedures Process Protocols documentation Recommendation Right atrial structure Route Secure Small Business Innovation Research Grant Staphylococcus aureus Staphylococcus epidermidis Sterilization Structure of jugular vein Superior vena cava structure Surface Technology Testing Thick Thinness Thrombosis Tissues Treatment Cost United States Veins Work biomaterial compatibility canine model commercialization cost design evaporation fungus genotoxicity hemocompatibility implantation improved improved outcome in vivo infection rate manufacture manufacturing process pathogen point of care preservation prevent prototype sheep model soluble complement C5b-9 systemic toxicity

项目摘要

PROJECT SUMMARY Approximately 80% of patients beginning hemodialysis (HD) in the United States use a catheter at treatment initiation, and 18.6% of all HD patients were using a catheter in 2017. However, the HD catheters (HDC) used for longer-term dialysis in patients have a high complication rate because of infections and dysfunction, with a catheter dysfunction rate of 0.5–3.42 episodes/1000 catheter-days. The most common catheter-related problems are infections (catheter-related bloodstream infections; CRBSI) and thrombosis. Fibrin sheath formation has a close relationship with pathogen colonization and biofilm formation on the catheter surface. The entry of pathogens into the bloodstream through the catheter-extraluminal and intraluminal routes and the seeding of pathogens that develop biofilm on the catheter surface cause CRBSI. In the US, annual HD treatment costs ~$89,000 per patient, with total costs of $42 billion. In 2016, 80% of patients used a catheter at initiation of HD and 18.6% of all HD patients in the US were using a catheter in 2017. However, no available solutions to prevent catheter dysfunction can successfully prevent both thrombosis and infection. FFMD is aiming to optimize and commercialize tethered liquid perfluorocarbon (TLP) coatings on medical devices. Our TLP coating stops the adhesion of all biological components (bacteria, fungi, blood components) to the surface of medical devices by immobilizing a thin layer of highly inert and biocompatible perfluorinated liquid. In preliminary work, we optimized our TLP coating technology for HDC by incorporating a thin fluoropolymer layer on the catheter surface. We also demonstrated that the optimized coating could reduce colonization by CRBSI pathogens by >85% vs. uncoated polyurethane catheter while also effectively reducing fibrinogen adhesion and thrombosis on the catheter surface. The objective of this Direct to Phase II SBIR application is to complete our path toward marketability with our TLP-modified HDC (TLP HDC). Using a previously established domestic sheep model, we will test the central hypothesis that TLP HDC will out-perform standard HDC by decreasing fibrin sheath formation, which has a close relationship with both catheter dysfunction and biofilm formation. This will be achieved using three aims. Aim 1: Compare the in vivo effectiveness of TLP HDC and standard HDC (Palindrome®) at reducing fibrin sheath formation and catheter tip occlusion. Aim 2: Obtain GMP-manufactured TLP HDC. Aim 3: Initiate the 510(k) application process to obtain FDA premarketing approval and perform a biocompatibility study. These advances will allow FFMD to maximize the effectiveness of the TLP coating and dramatically improve HD patient care by reducing catheter dysfunction and the CRBSI rate in clinical settings.

项目总结